Abstracts tagged "mesenchymal stem cells and rheumatoid arthritis (RA)"

Abstract Number: 2419 • 2017 ACR/ARHP Annual Meeting
Immunomodulatory Effects of Bone-Marrow Mesenchymal Stem Cells in Rheumatoid Arthitis: Influence of Disease Activity
Benjamín Fernández-Gutiérrez¹, Jose Ramon Lamas², Yaiza Lopiz³, Cristina Lajas⁴, Lydia A Alcazar⁵ and Luis Rodriguez-Rodriguez⁶, ¹Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, ²Rheumatology, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ³Cirugía Ortopédica y Traumatología, Hospital Clínico San Carlos, Madrid, Spain, ⁴Rheumatology Department, Hospital Clínical San Carlos, Madrid, Spain, ⁵Rheumatology Department and Heath Research Institute (IdISSC), Hospital Clinico San Carlos, Madrid, Spain, ⁶Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: To analyze the effect of demographic and clinical related characteristics of rheumatoid arthritis (RA) patients in the immunomodulatory effects of mesenchymal stem cells (MSCs).…
Abstract Number: 1445 • 2016 ACR/ARHP Annual Meeting
Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Ameliorate Rheumatoid Arthritis Via Regulation of Macrophage Activation and Polarization
Tae-Hoon Shin¹, Kichul Shin², Hyung-Sik Kim^3,4 and Kyung-Sun Kang⁵, ¹Adult Stem Cell Research Center, College of Veterinary Medicine, Seoul National University, Seoul, Korea, The Republic of, ²Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of, ³Busan National University School of Medicine, Busan, Korea, The Republic of, ⁴Biomedical Research Institute, Busan National University Hospital, Busan, Korea, The Republic of, ⁵Institute for Stem cell Regenerative Medicine, Kangstem Biotech, Seoul, Korea, The Republic of
Background/Purpose: Immunomodulatory properties enable mesenchymal stem cells (MSCs) to be a promising alternative for the treatment of a wide range of immune-related diseases including rheumatoid…
Abstract Number: 1575 • 2016 ACR/ARHP Annual Meeting
Transient Circulatory Existence of Multipotential Stromal Cells Is Unlikely to Contribute to the Pathogenesis of Rheumatoid Arthritis
Sarah Churchman¹, Sally Boxall¹, Elena Jones¹, Paul Emery¹, Peter Giannoudis^1,2 and Dennis McGonagle¹, ¹NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds,, Leeds, United Kingdom, ²Academic Department of Trauma and Orthopaedics, Leeds, United Kingdom
Background/Purpose: Circulating multipotential stromal cells (MSCs) also termed mesenchymal stem cells have previously been implicated in fibroblast mediated polyarticular joint destruction in rheumatoid arthritis (RA).…
Abstract Number: 526 • 2015 ACR/ARHP Annual Meeting
Citrullinated Fibrinogen Promotes Bone Marrow Mesenchymal Stem Cells to Assume a Proinflammatory Phenotype
Yue Sun, Wei Deng, Weiwei Chen, Genhong Yao, Xuebing Feng and Lingyun Sun, Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Mesenchymal stem cells (MSC) are not only immune-inhibitory cells, and may act as pro-inflammatory cells due to lack of a proper “licensing”. The role…
Abstract Number: 2343 • 2014 ACR/ARHP Annual Meeting
Therapeutic Effects of Mesenchymal Stem Cells, Anti-Tumor Necrosis Factor and Anti-CD20 Treatment on Collagen Induced Arthritis
Yue Sun¹, Xuebing Feng² and Lingyun Sun², ¹The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Department of Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose Tremendous progress has been made in the development of non-conventional therapies for rheumatoid arthritis (RA). In this study, the effects of mesenchymal stem cells…
Abstract Number: 1643 • 2013 ACR/ARHP Annual Meeting
Ex Vivo Suppression Of RA Effector T Cells (Teff) By Mapc Media Is Synergistic With Treg
Gali Malul¹, David Soler², Donald D. Anthony³, Hillard M. Lazarus⁴, Nicholas Lehman⁵, Thomas McCormick², Julia M. Sugalski⁶, Anthony E. Ting⁵ and Nora G. Singer⁷, ¹Rheumatology, MetroHealth Medical Center, Cleveland, OH, ²Dermatology, Case Medical Center, Cleveland, OH, ³Medicine, Case Western Reserve University, Cleveland, OH, ⁴Comprehensive Cancer Center, Case Medical Center, Cleveland, OH, ⁵Athersys, Inc., Cleveland, OH, ⁶Medicine/infectious disease, Case Western Reserve University, Cleveland, OH, ⁷Medicine, Division of Rheumatology, MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Use of mesenchymal/multipotent stem cells (MSCs/MAPCs) is an emerging immune modulatory therapeutic strategy promising for a number of human diseases. Multipotent adult progenitor cells…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].